ArticleBMC nephrology2026
Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum CXCL10 is one of the chemokines that is strongly associated with systemic lupus erythematosus (SLE) and its related complications, particularly lupus nephritis (LN). Our study aimed to validate serum CXCL10 as a potential biomarker of LN and disease activity, and to assess its association with organ damage in Egyptian patients.
methodsA cross-sectional study was conducted among 100 SLE patients recruited from Ain Shams University Hospital, with 50 patients in group I (without LN) and 50 in group II (with LN). All patients underwent a medical history review, clinical examination, and assessment of disease activity using the SLE Disease Activity Index (SLEDAI-2K) and the Renal SLEDAI (R-SLEDAI). Damage scores were recorded for each patient. Laboratory investigations, such as serum CXCL10, complete blood count (CBC), blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR), urine analysis, 24-h urinary protein excretion, antinuclear antibodies (ANA), anti-dsDNA antibodies, and serum complement (C3, C4).
resultsSerum CXCL10 levels were significantly elevated in patients with LN compared to those without (p < 0.001). Disease activity indices, renal function parameters, and damage scores were all increased in the LN group (p < 0.001). CXCL10 levels demonstrated strong positive correlations with 24-hour urinary protein, BUN, serum creatinine, disease activity and damage scores, and strong negative correlations with eGFR, C3, and C4 (all p < 0.001). Diagnostic accuracy analyses showed that serum CXCL10 predicted LN with 96% sensitivity and 94% specificity and was also predictive of renal and overall disease activity (sensitivity/specificity for R-SLEDAI: 100%/94.2%; for SLEDAI-2K: 81.97%/97.44%).
conclusionSerum CXCL10 is a promising non-invasive biomarker for identifying LN and monitoring disease activity in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.